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Cancer Incidence Among Pesticide Applicators Exposed
to Atrazine in the Agricultural Health Study
Jennifer A. Rusiecki, Anneclaire De Roos, Won Jin Lee, Mustafa Dosemeci, Jay
H. Lubin, Jane A. Hoppin, Aaron Blair, Michael C. R. Alavanja
Background: Atrazine is the most heavily applied agricultural pesticide for crop production in the United States. Both
animal and human studies have suggested that atrazine is
possibly carcinogenic, but results have been mixed. We evaluated cancer incidence in atrazine-exposed pesticide applicators among 53 943 participants in the Agricultural Health
Study, a prospective cohort study of licensed pesticide applicators in Iowa and North Carolina. Methods: We obtained
detailed pesticide exposure information using a selfadministered questionnaire completed at the time of enrollment (1993–1997). Cancer incidence was followed through
December 31, 2001. We used adjusted Poisson regression to
calculate rate ratios (RRs) and 95% confidence intervals
(CIs) of multiple types of cancer among atrazine exposed
applicators. Ptrend values were calculated using atrazine exposure as a continuous variable, and all statistical tests were
two-sided. Two exposure metrics were used: quartiles of
lifetime days of exposure and quartiles of intensity-weighted
lifetime days of exposure. Results: 36 513 (68%) applicators
reported ever using atrazine; exposure was not associated
with overall cancer incidence. Comparisons of cancer incidence in applicators with the highest atrazine exposure and
those with the lowest exposure, assessed by lifetime days
(RRLD) and intensity-weighted lifetime days (RRIWLD) of
exposure yielded the following results: prostate cancer,
RRLD ⴝ 0.88, 95% CI ⴝ 0.63 to 1.23, Ptrend ⴝ .26, and
RRIWLD ⴝ 0.89, 95% CI ⴝ 0.63 to 1.25, Ptrend ⴝ .35; lung
cancer, RRLD ⴝ 1.91, 95% CI ⴝ 0.93 to 3.94, Ptrend ⴝ .08,
and RRIWLD ⴝ 1.37, 95% CI ⴝ 0.65 to 2.86, Ptrend ⴝ .19;
bladder cancer, RRLD ⴝ 3.06, 95% CI ⴝ 0.86 to 10.81, Ptrend
ⴝ.18, and RRIWLD ⴝ 0.85, 95% CI ⴝ 0.24 to 2.94, Ptrend ⴝ
.71; non-Hodgkin lymphoma, RRLD ⴝ 1.61, 95% CI ⴝ 0.62
to 4.16, Ptrend ⴝ .35, and RRIWLD ⴝ 1.75, 95% CI ⴝ 0.73 to
4.20, Ptrend ⴝ .14; and multiple myeloma, RRLD ⴝ 1.60, 95%
CI ⴝ 0.37 to 7.01, Ptrend ⴝ .41, and RRIWLD ⴝ 2.17, 95% CI
ⴝ 0.45 to 10.32, Ptrend ⴝ .21. Conclusions: Our analyses did
not find any clear associations between atrazine exposure
and any cancer analyzed. However, further studies are warranted for tumor types in which there was a suggestion of
trend (lung, bladder, non-Hodgkin lymphoma, and multiple
myeloma). [J Natl Cancer Inst 2004;96:1375– 82]
Atrazine (2-chloro-4-ethylamino-6-isopropylamino)-s-triazine is
a triazine herbicide that is used primarily on corn and soybean
crops to control growth of broadleaf and grassy weeds. It is the
most heavily used agricultural pesticide in the United States,
with an estimated 76.4 million pounds applied annually (1).
Human exposure to atrazine occurs occupationally in farming
and manufacturing and environmentally through contaminated
drinking water or drift. Atrazine is the most commonly detected
pesticide in surface water in surveys in the midwestern United

States and was the second most frequently detected pesticide in
the U.S. Environmental Protection Agency (EPA) National Survey of Pesticides in Drinking Water Wells (2). Use of atrazine
has been restricted since 1993, primarily to protect water supplies (2). Only licensed pesticide applicators may purchase
atrazine.
Results from animal and human studies on the carcinogenic
effects of exposure to atrazine have been mixed. Oral administration of atrazine was associated with increased incidence and
earlier onset of mammary tumors in female Sprague–Dawley
rats but not in other strains of rats or in other mammals (3,4).
Atrazine exposure was also associated with lymphomas and
testicular cancer in rats and mice in some studies (5–7). Several
epidemiologic studies in humans have evaluated cancer risks
associated with atrazine exposure (8 –22). Slightly greater than
expected numbers of bladder, oral cavity, and lymphohematopoietic cancers were observed in a cohort of triazine herbicide
manufacturing workers; however, none of the increases were
statistically significant, and the people in the study were exposed
to carcinogens other than atrazine (8). This study also found
statistically significantly elevated standardized incidence ratios
(SIRs) for prostate cancer (SIR ⫽ 3.94, 95% confidence interval
[CI] ⫽ 1.28 to 9.20); however, this increase may have been due
to the intensive prostate-specific antigen (PSA) screening of the
workers in this cohort (8). A mortality study based on the same
population also found an increased standardized mortality ratio
for non-Hodgkin lymphoma (standardized mortality ratio ⫽
3.72, 95% CI ⫽ 1.01 to 9.52) (9). However, no association was
found between atrazine exposure and prostate cancer in a study
by Alavanja et al. (10) of the Agricultural Health Study cohort,
a cohort of pesticide applicators from Iowa and North Carolina
enrolled from January 1, 1993, through December 31, 1997.
In case– control studies conducted in the midwestern United
States, atrazine or triazine use was not associated with Hodgkin
disease (11), leukemia (12), multiple myeloma (13), soft tissue
sarcoma (11), or colon cancer (14). Atrazine use was weakly or
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moderately associated with non-Hodgkin lymphoma (NHL) in
case– control studies conducted in Iowa and Minnesota (15),
Kansas (11), and Nebraska (16,17), although the association in
the Nebraska study was diminished after adjustment for exposure to 2,4-dichlorophenoxyacetic acid (2,4-D) and organophosphate insecticides (16). However, a pooled analysis by De Roos
et al. (18) of data from these studies found statistically significantly increased odds ratios (ORs) for NHL with atrazine exposure in combination with exposure to one of three other pesticides (diazinon, alachlor, or dicamba). A case– control study of
ovarian cancer found an increased risk among women farmers
“possibly” and “definitely” exposed to atrazine in their occupation (19). Ecologic studies have shown increased risks of stomach (20), prostate, brain, testicular (21), and breast cancers (22)
and leukemia and decreased risks of colon (20) and breast
cancers (23) with increasing amounts of triazine herbicides
applied or with increasing levels measured in drinking water.
Based on inadequate data for humans and limited data for
experimental animals, atrazine was classified as “possibly carcinogenic to humans” (Group 2B) by the International Agency
for Research on Cancer in 1999 (24). The EPA has classified
atrazine as “not likely to be a human carcinogen” (25). However,
the limited data on the effects of atrazine among humans, the
provocative findings in animal studies, and the frequency with
which this herbicide is used warrant further investigation among
exposed populations. We therefore investigated site-specific
cancer incidence and risk among pesticide applicators exposed
to atrazine in the Agricultural Health Study cohort using a longer
follow-up period and a larger number of case patients than the
prostate cancer analysis by Alavanja et al. (10).

SUBJECTS

AND

METHODS

Cohort Enrollment and Follow-up
The Agricultural Health Study cohort is a prospective study
of 57 311 private and commercial applicators licensed to apply
restricted-use pesticides who live in Iowa or North Carolina and
who were recruited between 1993 and 1997 (26). Cohort members were matched to cancer registry files in Iowa and North
Carolina for case identification and to the state death registries
and the National Death Index to ascertain vital status. Incident
cancers were identified for the time period from the date of
enrollment through December 31, 2001, and were coded according to the International Classification of Diseases for Oncology,
2nd edition (ICD-O-2). Cohort members who were alive but no
longer residing in Iowa or North Carolina were identified
through current address records of the Internal Revenue Service
(address information only), Motor Vehicle Registration offices,
and pesticide license registries of the state agricultural departments. Person-year accumulation for cancer incidence of individuals who had moved from the state was censored in the year
they departed, although they were still followed up for mortality.
The mean time of follow-up was 6.5 years. All participants
provided verbal informed consent, and the protocol was approved by the institutional review boards of the National Cancer
Institute, Batelle, the University of Iowa, and Westat.
Exposure Assessment
A self-administered enrollment questionnaire collected
comprehensive exposure data on 22 pesticides and informa1376 ARTICLES

tion on ever/never use for 28 more pesticides, use of personal
protective equipment, pesticide application methods, pesticide mixing, equipment repair, smoking history, alcohol consumption, cancer history of first-degree relatives, and basic
demographics (27). Applicators who completed this questionnaire were also given a self-administered take-home questionnaire, which sought additional information on occupational exposures. The questionnaires may be accessed at
http://www.aghealth.org/questionnaires.html.
Data from questionnaires completed at enrollment and measurement data from the pesticide exposure literature were used to
calculate estimated intensity of exposure to each pesticide using
the following algorithm: intensity level ⫽ ([mixing status ⫹
application method ⫹ equipment repair status] ⫻ personal protective equipment use) (28).
The scores assigned to each factor in the intensity-level
algorithm were not assigned as nominal or ordinal values but
were weighted to reflect intensity of exposure as described in the
literature. Mixing status (mix) was a three-level variable based
on never mixing, personally mixing less than 50% of the time,
and personally mixing more than 50% of the time (mix ⫽ 0, 3,
and 9, respectively). Application method (applic) was a six-level
variable based on never applying, use of aerial-aircraft or distribution of tablets, application in furrow, use of boom on
tractor, use of backpack, and use of hand spray (applic ⫽ 0, 1,
2, 3, 8, 9, respectively). Equipment repair status (repair) was a
two-level variable based on not repairing or repairing (repair ⫽
0, 2, respectively). Personal protective equipment use was an
eight-level variable based on type of personal protective equipment used while applying pesticides (28).
We constructed two lifetime atrazine exposure metrics for
this analysis, each categorized into quartiles, based on the quartile levels among all cancer cases: 1) lifetime days of exposure,
based on the product of the midpoints of the questionnaire
categories of number of years an applicator personally applied or
mixed atrazine and number of days in an average year an
applicator personally mixed or applied atrazine (i.e., years of use
⫻ number of days used per year, resulting in the following
quartiles: ⱕ19.9, 20.0 –56.0, 56.1–178.5, ⱖ178.5) and
2) intensity-weighted lifetime days of exposure, which was the
product of lifetime days of exposure and intensity level (i.e.,
years of use ⫻ number of days used per year ⫻ intensity level,
resulting in the following quartiles: ⱕ101.9, 102.0 –326.7,
326.8 –911.4, ⱖ911.4).
Statistical Analysis
Prevalent cancer case patients identified at or prior to the time
of enrollment (n ⫽ 1074) and applicators who did not provide
information on atrazine use (n ⫽ 2294) were excluded from this
analysis, leaving 53 943 applicators. Analyses of first primary
incident cancer case patients enabled us to obtain exposure data
from each case patient prior to the onset of cancer.
To examine internal exposure–response relationships among
participants who reported having ever used atrazine, Poisson
regression analyses were carried out for individual cancer sites
to estimate rate ratios (RRs) and 95% confidence intervals (CIs)
associated with quartiles of lifetime days of exposure (RRLD) or
intensity-weighted lifetime days of exposure (RRIWLD), using
the lowest quartile as the referent. We investigated only cancer
sites for which there were at least 20 case patients with atrazine
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exposure. P values for trend were calculated using atrazine
exposure as a continuous variable, and all statistical tests were
two-sided. Rate ratios were adjusted for age at enrollment (as a
continuous variable), sex, educational level (high school/GED or
lower, beyond high school), alcohol consumption (ever/never),
family history of cancer in first-degree relatives (yes/no), state of
residence (Iowa/North Carolina), and cigarette smoking history
(never/low/high: the median value of pack-years [11.25] among
smokers was used to classify low and high categories of smokers). In addition, we carried out the same Poisson analyses
described above and included second primary incident cancers
as case patients (i.e., both first and second primary cancer case
patients were included) to increase the numbers of case patients.
Variation ranged from one additional case patient with esophageal cancer and leukemia to 28 additional case patients with
prostate cancer.
To ensure the use of the most appropriate reference group—
either applicators never exposed to atrazine or applicators exposed to atrazine in the lowest exposure quartile—we carried out
a comparison of baseline characteristics between different types
of pesticide applicators: 1) applicators never exposed to atrazine,
2) applicators with atrazine exposure in the lowest quartile of
lifetime days of exposure, and 3) applicators with atrazine exposure in the highest three quartiles of lifetime days of exposure.
We postulated that applicators with baseline characteristics similar to those of the applicators in the highest exposure group
would be most appropriate as a reference group for the Poisson
regression analyses. Too much difference with respect to these
baseline characteristics might introduce residual confounding
from a variety of unidentified sources.
Potential confounding from exposure to other pesticides was
controlled by adjusting exposure to 10 other pesticides (dicamba, cyanazine, alachlor, trifluralin, 2,4-D, chlorimuronethyl,
metribuzine, butylate, phorate, and heptachlor). These pesticides
were identified as the 10 most strongly correlated with atrazine
out of 50 pesticides measured in the Agricultural Health Study,
based on either strength of the correlation coefficient for
intensity-weighted lifetime days of exposure (highest: r ⫽ .78;
lowest: r ⫽ .58) or strength of association for ever/never comparison between atrazine and each of the 28 pesticides in the
Agricultural Health Study for which there is ever/never data
only. None of the pesticides we evaluated was negatively correlated with atrazine. In the final models, exposure levels of
dicamba, cyanazine, alachlor, trifluralin, and 2,4-D were categorized as never, low, and high. The low and high group of each
pesticide was classified by the median intensity-weighted
exposure-days of each pesticide. For the pesticides chlorimuronethyl, metribuzine, butylate, phorate, and heptachlor, we had
information only on ever/never use, so these five were categorized as such.

RESULTS
Selected characteristics of the atrazine exposed (lowest quartile and combined highest three quartiles) and nonexposed applicators in the Agricultural Health Study cohort are presented in
Table 1. Among 53 943 subjects with complete exposure information, 36 513 (68%) reported ever having used atrazine, and
they contributed a total of 237 045 person-years to the analysis.
The cohort, both exposed and nonexposed, comprised primarily
white, male, private applicators with relatively low smoking

rates; in both the exposed and nonexposed groups, about half the
subjects reported that they had never smoked. Exposed and
nonexposed subjects were similar with respect to age, smoking
history, alcohol consumption, educational level, and family history of cancer in a first-degree relative. The group consisting of
the lowest exposed quartile is observed to be more similar to the
group comprising the highest three quartiles than is the nonexposed group on a number of important variables. These include
applicator status (i.e., private/commercial), state of residence,
involvement in corn production, and use of the 10 pesticides
most highly correlated with atrazine. Because of these similarities, we determined that the most appropriate reference group
for the exposure–response analyses was applicators in the lowest
quartile of atrazine exposure. However, to ensure that we did not
overlook any potential associations and to verify our findings,
we also carried out exposure–response analyses using the nonexposed applicators as the reference group (data not shown).
The Poisson regression rate ratios of selected cancers for
which there were at least 20 atrazine-exposed case patients are
presented in Table 2. For all cancers combined, there was no
statistically significantly increased risk with increasing quartiles
of lifetime days of exposure to atrazine or intensity-weighted
lifetime days of exposure. Prostate cancer was the most frequent
cancer in the cohort (n ⫽ 554); we did not detect any increased
risk for prostate cancer with increasing atrazine exposure,
whether assessed using lifetime days of exposure (highest quartile: RR ⫽ 0.88, 95% CI ⫽ 0.63 to 1.23; Ptrend ⫽ .26) or
intensity-weighted lifetime days of exposure (highest quartile:
RR ⫽ 0.89, 95% CI ⫽ 0.63 to 1.25; Ptrend ⫽ .35), even in
subjects exposed for more than 178.5 days. We detected a
statistically nonsignificant increased risk for lung cancer with
increasing quartiles of lifetime days of exposure (highest quartile: RRLD ⫽ 1.91, 95% CI ⫽ 0.93 to 3.94; Ptrend ⫽ .08). The
risk of lung cancer with intensity-weighted lifetime days of
exposure, however, was less consistent across quartiles and
diminished somewhat compared with that of lifetime days of
exposure in the highest exposure quartile (RRIWLD ⫽ 1.37, 95%
CI ⫽ 0.65 to 2.86). Further analyses among never smokers,
former smokers, and current smokers showed that the rate ratios
of lung cancer were increased only in former smokers. However,
we did not detect a statistically significant interaction between
atrazine exposure and smoking history with respect to lung
cancer. For bladder cancer, we also found no association between risk and exposure. A statistically nonsignificantly increased risk was observed with lifetime days of exposure (highest quartile: RRLD ⫽ 3.06, 95% CI ⫽ 0.86 to 10.81; Ptrend ⫽ .18)
but not with intensity-weighted lifetime days of exposure (highest quartile: RRIWLD ⫽ 0.85, 95% CI ⫽ 0.24 to 2.94). Elevated
risks were suggested for NHL for both the analysis using lifetime days of exposure and the analysis using intensity-weighted
lifetime days of exposure (highest quartile: RRLD ⫽ 1.61, 95%
CI ⫽ 0.62 to 4.16, Ptrend ⫽ .35; highest quartile: RRIWLD ⫽
1.75, 95% CI ⫽ 0.73 to 4.20, Ptrend ⫽ .14) and multiple myeloma (highest quartile: RRLD ⫽ 1.60, 95% CI ⫽ 0.37 to 7.01,
Ptrend ⫽ .41; highest quartile: RRIWLD ⫽ 2.17, 95% CI ⫽ 0.45
to 10.32, Ptrend ⫽ .21). However, the numbers of applicators
with NHL (n ⫽ 68) and multiple myeloma (n ⫽ 23) were small,
RR estimates were not statistically significant, and there were no
indications of a linear dose-response trend. We found no evidence of increased risks for cancers of the oral cavity, colon,
rectum, pancreas, or kidney or for melanoma or leukemia.
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Table 1. Selected characteristics of applicators by atrazine exposure in the Agricultural Health Study based on 1993–1997 enrollment data
Nonexposed group,
No. (%)
(n ⫽ 17 430)

Lowest exposed quartile,
No. (%)
(n ⫽ 9566)ⴱ

Highest three quartiles
combined, No. (%)
(n ⫽ 26 947)†

6741 (38.7)
4064 (23.3)
3121 (17.9)
3504 (20.1)

3012 (31.5)
2761 (28.9)
1933 (20.2)
1859 (19.4)

7906 (29.3)
8191 (30.4)
6038 (22.4)
4811 (17.9)

16 272 (93.4)
1158 (6.6)

9439 (98.7)
127 (1.3)

26 759 (99.3)
188 (0.7)

8684 (49.8)
8746 (50.2)

6787 (71.0)
2779 (29.0)

19 875 (73.8)
7072 (26.2)

15 010 (86.1)
2420 (13.9)

9208 (96.3)
358 (3.7)

24 952 (92.6)
1995 (7.4)

8671 (49.7)
3941 (22.6)
4135 (23.7)
683 (4.0)

5244 (54.8)
2050 (21.4)
2005 (21.0)
267 (2.8)

14 523 (53.9)
5815 (21.6)
5847 (21.7)
762 (2.8)

6267 (36.0)
10 113 (58.0)
1050 (6.0)

2847 (29.8)
6318 (66.0)
401 (4.2)

7415 (27.5)
18 740 (69.5)
792 (3.0)

Educational level
High school/GED or lower
Beyond high school
Missing

9722 (55.8)
7254 (41.6)
454 (2.6)

5348 (55.9)
4037 (42.2)
181 (1.9)

14 934 (55.4)
11 505 (42.7)
508 (1.9)

Family history of cancer in first-degree relatives
No
Yes
Missing

9812 (56.3)
5521 (31.7)
2097 (12.0)

5140 (53.7)
3554 (37.2)
872 (9.1)

14 369 (53.3)
10 491 (38.9)
2087 (7.8)

Corn production
No
Yes

9764 (56.0)
7666 (44.0)

2293 (24.0)
7273 (76.0)

4879 (18.1)
22 068 (81.9)

Ever exposure to 10 pesticides most highly correlated with atrazine
Dicamba
Cyanazine
Alachlor
Trifluralin
2,4-Dichlorophenoxyacetic acid
Chlorimuronethyl
Metribuzin
Butylate
Phorate
Heptachlor

3713 (23.6)§
1636 (10.4)§
3452 (22.1)§
4055 (26.1)§
8954 (52.1)§
2538 (16.7)§
2540 (16.7)§
1328 (8.8)§
2091 (13.8)§
847 (5.6)§

4940 (56.5)㛳
3686 (42)㛳
4815 (54.7)㛳
5030 (57.0)㛳
7586 (80.0)㛳
3010 (34.6)㛳
3901 (44.8)㛳
2295 (26.5)㛳
2714 (31.2)㛳
1113 (12.9)㛳

16 246 (63.9)¶
15 258 (59.6)¶
17 872 (69.5)¶
16 989 (66.2)¶
23 160 (86.5)¶
13 144 (52.1)¶
15 528 (61.5)¶
11 896 (47.3)¶
10 783 (42.9)¶
5201 (20.9)¶

Characteristics
Age, y
⬍40
40–49
50–59
ⱖ60
Sex
Male
Female
State of residence
Iowa
North Carolina
Applicator type‡
Private
Commercial
Smoking history
Never
Low (⬍11.25 pack-years)
High (ⱖ11.25 pack-years)
Missing
Alcohol consumption
No
Yes
Missing

ⴱFirst quartile of lifetime days of exposure (years of use ⫻ days of use per year).
†Second, third, and fourth quartiles of lifetime days of exposure (years of use ⫻ days of use per year).
‡“Private applicators” refers primarily to individual farmers and “commercial” refers to professional pesticide applicators.
§Ever exposed to indicated chemical but not to atrazine (thus, numbers in columns do not sum to 100%).
㛳Ever exposed to indicated chemical and in lowest quartile of atrazine exposure (thus, numbers in columns do not sum to 100%).
¶Ever exposed to indicated chemical and in the highest three quartiles of atrazine exposure (thus, numbers in columns do not sum to 100%).

Cancer risk patterns were similar when we used never
exposed applicators as the reference group, making comparisons for each of the four quartiles of atrazine exposure (data
not shown). For prostate cancer, there was no increased risk,
whether we used lifetime days of exposure (Q1, RRLD ⫽
0.98; Q2, RRLD ⫽ 0.87; Q3, RRLD ⫽ 0.74; Q4, RRLD ⫽ 0.83;
Ptrend ⫽ .09) or intensity-weighted lifetime days of exposure
(Q1, RRIWLD ⫽ 0.91; Q2, RRIWLD ⫽ 0.94; Q3, RRIWLD ⫽
0.78; Q4, RRIWLD ⫽ 0.79; Ptrend ⫽ .11). For both lung and
bladder cancers, there were statistically nonsignificantly elevated rate ratios only for the highest quartile of lifetime days
of exposure; again, for intensity-weighted lifetime days of
1378 ARTICLES

exposure, the effect was diminished in the highest quartile.
For NHL, there was a steadily increasing, statistically nonsignificant linear trend for quartiles of both exposure metrics
(highest quartile: RRLD ⫽ 2.16, 95% CI ⫽ 0.84 to 5.59, Ptrend
⫽ .06; highest quartile: RRIWLD ⫽ 2.78, 95% CI ⫽ 1.16 to
6.68, Ptrend ⫽ .02). For multiple myeloma, there was a similar
pattern for both metrics (highest quartile: RRLD ⫽ 4.75, 95%
CI ⫽ 0.68 to 33.08, Ptrend ⫽ .14; highest quartile: RRIWLD ⫽
4.71, 95% CI ⫽ 0.72 to 30.69, Ptrend ⫽ .07). For all other
cancers investigated, no associations were found when applicators never exposed to atrazine were used as the comparison
group.
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Table 2. Rate ratios (RRs) and 95% confidence intervals (CIs) from Poisson regressions for selected cancersⴱ by lifetime days of exposure and intensityweighted days of exposure to atrazine† among Agricultural Health Study cohort applicators

Cancer site

Exposure to atrazine

Exposure days
(quartiles)‡

N§

1–20
21–56
57–178.5
⬎178.5

1361
357
348
358
298

1–20
21–56
57–178.5
⬎178.5

38
9
19
5
5

1.00 (referent)
1.93 (0.71 to 5.25)
0.69 (0.20 to 2.38)
0.50 (0.11 to 2.24)

1–20
21–56
57–178.5
⬎178.5

20
4
8
7
1

1.00 (referent)
1.69 (0.39 to 7.28)
0.77 (0.14 to 4.23)
0.29 (0.03 to 3.35)

1–20
21–56
57–178.5
⬎178.5

110
28
22
35
25

1–20
21–56
57–178.5
⬎178.5

52
11
8
17
16

1–20
21–56
57–178.5
⬎178.5

21
4
9
5
3

1–20
21–56
57–178.5
⬎178.5

118
27
25
37
29

1–20
21–56
5–178.5
⬎178.5

52
12
12
13
15

1–20
21–56
57–178.5
⬎178.5

554
160
135
143
116

1–20
21–56
57–178.5
⬎178.5

47
10
12
9
16

1.00 (referent)
2.25 (0.67 to 7.62)
1.04 (0.27 to 4.05)
3.06 (0.86 to 10.81)

1–20
21–56
57–178.5
⬎178.5

40
12
8
11
9

1.00 (referent)
0.78 (0.27 to 2.33)
0.33 (0.08 to 1.32)
0.58 (0.15 to 2.25)

1–20
21–56
57–178.5
⬎178.5

68
17
19
17
15

1–20
21–56
57–178.5
⬎178.5

23
7
4
5
7

All cancers

Oral cavity

Esophagus

Colon

Rectum

Pancreas

Lung

Melanoma

Prostate

Bladder

Kidney

Non-Hodgkin lymphoma

Multiple myeloma

RRLD (95% CI)㛳
1.00 (referent)
1.05 (0.87 to 1.27)
0.90 (0.74 to 1.11)
1.01 (0.82 to 1.26)

1.00 (referent)
0.79 (0.40 to 1.57)
1.12 (0.59 to 2.10)
0.88 (0.41 to 1.89)
1.00 (referent)
1.11 (0.41 to 3.00)
0.97 (0.35 to 2.69)
1.38 (0.47 to 4.02)
1.00 (referent)
1.26 (0.27 to 5.84)
1.14 (0.24 to 5.49)
1.13 (0.19 to 6.61)
1.00 (referent)
0.87 (0.40 to 1.87)
1.13 (0.56 to 2.29)
1.91 (0.93 to 3.94)
1.00 (referent)
1.06 (0.44 to 2.56)
1.18 (0.50 to 2.79)
1.05 (0.39 to 2.84)
1.00 (referent)
0.89 (0.66 to 1.21)
0.75 (0.56 to 1.03)
0.88 (0.63 to 1.23)

1.00 (referent)
1.56 (0.66 to 3.69)
1.59 (0.67 to 3.79)
1.61 (0.62 to 4.16)
1.00 (referent)
0.57 (0.10 to 3.13)
1.19 (0.31 to 4.65)
1.60 (0.37 to 7.01)

Ptrend¶

N§

RRIWLD (95% CI)#

Ptrend¶

.68

1355
340
338
338
339

1.00 (referent)
0.97 (0.80 to 1.18)
0.96 (0.79 to 1.18)
0.88 (0.71 to 1.11)

.28

.18

38
12
10
10
6

1.00 (referent)
0.74 (0.25 to 2.16)
0.86 (0.30 to 2.47)
0.36 (0.10 to 1.38)

.20

.27

20
3
8
6
3

1.00 (referent)
5.57 (0.63 to 49.05)
3.03 (0.29 to 31.62)
2.70 (0.23 to 31.21)

.77

.98

108
30
24
21
33

1.00 (referent)
0.65 (0.33 to 1.28)
0.61 (0.30 to 1.25)
0.86 (0.43 to 1.73)

.64

.65

52
12
8
14
18

1.00 (referent)
0.79 (0.29 to 2.16)
0.88 (0.32 to 2.42)
0.84 (0.29 to 2.44)

.79

.97

21
4
9
5
3

1.00 (referent)
0.96 (0.23 to 4.00)
0.57 (0.11 to 2.90)
0.56 (0.10 to 3.10)

.42

.08

117
27
19
37
34

1.00 (referent)
0.69 (0.30 to 1.57)
1.56 (0.78 to 3.14)
1.37 (0.65 to 2.86)

.19

.84

52
14
10
17
11

1.00 (referent)
0.57 (0.22 to 1.46)
1.31 (0.59 to 2.92)
0.41 (0.14 to 1.20)

.36

.26

552
143
143
132
134

1.00 (referent)
1.03 (0.76 to 1.41)
0.86 (0.62 to 1.20)
0.89 (0.63 to 1.25)

.35

.18

47
10
14
12
11

1.00 (referent)
1.21 (0.39 to 3.74)
1.01 (0.31 to 3.29)
0.85 (0.24 to 2.94)

.71

.22

40
13
8
8
11

1.00 (referent)
0.10 (0.01 to 0.83)
0.50 (0.15 to 1.63)
0.43 (0.12 to 1.54)

.27

.35

68
17
16
15
20

1.00 (referent)
0.88 (0.35 to 2.27)
1.36 (0.56 to 3.28)
1.75 (0.73 to 4.20)

.14

.41

23
6
2
7
8

1.00 (referent)
0.71 (0.12 to 4.30)
1.85 (0.42 to 8.24)
2.17 (0.45 to 10.32)

.21

(Tables continues)
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Table 2 (continued).

Cancer site

Exposure to atrazine

Exposure days
(quartiles)‡

N§

RRLD (95% CI)㛳

1–20
21–56
57–178.5
⬎178.5

41
9
12
10
10

1.00 (referent)
1.04 (0.39 to 2.74)
0.61 (0.21 to 1.78)
0.57 (0.17 to 1.91)

Leukemia

Ptrend¶

N§

RRIWLD (95% CI)#

Ptrend¶

.22

40
7
16
6
11

1.00 (referent)
1.64 (0.63 to 4.25)
0.41 (0.11 to 1.49)
0.56 (0.17 to 1.86)

.11

ⴱCancers for which there were at least 20 exposed case patients or an a priori hypothesis about an association with atrazine. Rate ratio adjusted for age, sex, alcohol
consumption, residence on a farm, smoking status, educational level, family history of cancer, state of residence, and use of 10 most highly correlated pesticides
with atrazine.
†Total number exposed to atrazine ⫽ 36 513.
‡Quartiles for lifetime days of exposure. Units for intensity-weighted lifetime days of exposure are not displayed in this table because they do not have an intrinsic
value.
§Number of cancer-specific case patients exposed to atrazine (total and for each quartile of exposure).
㛳RRLD ⫽ rate ratio of lifetime days of exposure (i.e., years of use ⫻ number of days of use per year).
¶P values were two-sided.
#RRIWLD ⫽ rate ratio of intensity-weighted lifetime days of exposure (i.e., years of use ⫻ number of days of use per year ⫻ intensity index).

We carried out the same Poisson analyses described above
and included second primary incident cancers as case patients
(i.e., both first and second primary cancer case patients included;
data not shown) to increase the numbers of case patients. Variation ranged from one additional case patient with esophageal
cancer and leukemia to 28 additional case patients with prostate
cancer. The results did not differ substantially from those presented in Table 2.

DISCUSSION
We found no associations between cancer incidence and
atrazine exposure, whether atrazine was analyzed as a cumulative measure (lifetime days of exposure) or as an intensityweighted cumulative measure (intensity-weighted lifetime days
of exposure). Although rate ratios for NHL, multiple myeloma,
lung cancer, and bladder cancer increased with both lifetime
days and intensity-weighted lifetime days of atrazine exposure,
confidence intervals were wide, and tests for trend were not
statistically significant. Similar results were seen whether we
used applicators in the lowest exposed quartile or applicators
never exposed to atrazine as the reference group.
A recent study of cancer incidence among triazine herbicide
manufacturing workers in a plant in Louisiana found a statistically significant excess of prostate cancer for actively working
company employees (excluding contract or inactive company
employees), compared with the general population in that region
(SIR ⫽ 394, 95% CI ⫽ 128 to 902) (8). However, the high
observed incidence of prostate cancer in the Louisiana plant
workers may have been due to the frequent PSA testing of these
employees, 98% of whom had at least one PSA test before the
age of 45. Of the 11 cases, nine were diagnosed at an early
clinical stage. In our study, there was considerable power to
investigate risk of prostate cancer (1-␤ ⫽ 0.89 to detect a rate
ratio of 1.3 in the highest quartile, assuming a trend over all
quartiles) with atrazine exposure, and we found no increased
risk, even for those who had applied atrazine for more than 178.5
days (the highest quartile of exposure) or had the highest
intensity-weighted lifetime days of exposure.
Our data suggest no clear association between NHL and
multiple myeloma incidence and atrazine exposure. However,
we did see some evidence of such an association, and further
1380 ARTICLES

follow-up is needed to determine whether such an association
exists. The only other prospective study on cancer and atrazine
is from a cohort of triazine herbicide manufacturing workers, in
which there were increased standardized incidence ratios for all
lymphatic and hematopoietic cancers (n ⫽ 7, 4.4 expected),
NHL (n ⫽ 3, 2.3 expected), and multiple myeloma (n ⫽ 2, 0.4
expected) among a group of men with “definite” or “probable”
exposure (8). A mortality study based on the same population
detected increased standardized mortality ratios for NHL (n ⫽ 4,
1.1 expected); however, the data did not have statistical power to
show trends in rates by years worked and years since hire (9).
Increased risk of NHL in men was associated with atrazine use
after adjustment for other commonly used pesticides in a pooled
analysis of the NCI-sponsored case– control studies conducted in
Nebraska, Kansas, and Iowa/Minnesota (18). This study also
found some evidence of a possible interaction between exposure
to atrazine and other pesticides and the risk of NHL. The number
of NHL cases in the Agricultural Health Study cohort is too
small to provide the statistical power to attempt such an analysis
at the present time. In an analysis of NHL by presence or
absence of the t(14;18) chromosomal translocation, a statistically significant increased risk was associated with atrazine
exposure for patients with the translocation, but not among those
lacking it (29), suggesting that further refinement of case definition in future studies may be worthwhile. A previous case–
control study observed a weak association between atrazine
exposure and multiple myeloma incidence (OR ⫽ 1.3, 95% CI
not reported) (13), whereas another study found no association
(OR ⫽ 0.8, 95% CI ⫽ 0.4 to 1.6) between multiple myeloma and
mixing, handling, or applying atrazine (30).
Slight suggestions of increased risk were found for lung and
bladder cancer in the highest quartile of lifetime days of exposure to atrazine. However, the rate ratios in the intensityweighted lifetime days of exposure analyses were weak for lung
cancer and essentially null for bladder cancer. We also found
similar patterns using the never exposed applicators as a reference group. Because the respiratory system may be an important
route of exposure for lung cancer, use of the intensity algorithm,
which weighs dermal exposure more heavily, may have increased measurement error. We further investigated the relationship between lung cancer and atrazine by stratifying the popu-
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lation into never smokers, former smokers, and current smokers.
That the rate ratios were highest among former smokers and null
among current smokers suggests that our findings of a slight
increase in risk may not be attributable solely to smoking. To our
knowledge, there are no a priori hypotheses for an association
between atrazine exposure and lung cancer. However, atrazine
was found in lung tissue at autopsy of a suicide victim poisoned
by ingestion of an herbicide mix containing atrazine (31). The
lung was one of the organs that showed the highest concentrations of atrazine. The inconsistencies between the two analyses
for bladder cancer leave us doubtful. We will continue to follow
up both cancers with respect to atrazine exposure.
The toxicologic activity of atrazine in humans is unclear.
Toxicity studies have examined various endpoints from atrazine
exposure, including carcinogenicity, genotoxicity, endocrine
disruption, and immunotoxicity. The majority of animal studies
indicate that atrazine has low genotoxicity, but there has been no
study of genotoxicity in humans. In male and female rats,
atrazine disrupts hypothalamic stimulation of pituitary function,
resulting in attenuation of luteinizing hormone levels (24). This
mechanism results in increased rates of mammary tumors in
some strains of female rats. In male rats, atrazine causes decreased production of testosterone by Ledig cells (32) and reduced seminal vesicle and prostate weights (32). However, the
potential for endocrine disruption in humans from atrazine exposure and its implications for carcinogenesis are not known.
Several studies have observed immunotoxicity of atrazine in
animals in vivo and in human and animal cells in vitro; however,
the evidence to date has not established the immune system as a
target for atrazine toxicity. Two studies in rodents showed that
atrazine exposure decreased levels of circulating lymphocytes,
although several other immune parameters were unchanged
(33,34). Several recent studies have observed impaired immune
function associated with administration of atrazine to cells in
vitro, including impaired cytokine production (interferon ␥, interleukin 5, and tumor necrosis factor-␣) by human peripheral
blood mononuclear cells (35) and decreased ability of human
natural killer cells to lyse tumor cells (36). Immunotoxicity may
be particularly relevant for lymphohematopoietic cancers.
The Agricultural Health Study has several important
strengths. It is the largest study to date of pesticide applicators
exposed to atrazine. Exposure information was gathered prior to
cancer diagnosis, thereby minimizing recall bias. In general,
farmers provide reliable information and considerable detail
regarding their pesticide application history (37– 40). The Agricultural Health Study cohort consists of licensed pesticide applicators who are responsible for thoroughly understanding pesticide regulations and for purchasing and applying chemicals on
their farms (41). Recall of pesticide use by the Agricultural
Health Study cohort has been shown to be consistent with the
dates these pesticides came on the market (41). To our knowledge, this is the first human study of atrazine to use a semiquantitative method to assess exposure; comprehensive questionnaire
data were used to quantify atrazine exposure levels, providing
greater discrimination between high and low exposures than
previous studies that broadly defined exposure as “ever used”
atrazine. In addition, detailed information on the use of many
common pesticides and lifestyle characteristics allowed us to
adjust for potential confounding factors.
Certain limitations of our data reduce the number and kinds
of inferences we can make regarding atrazine and its association

with specific cancers. Although the Agricultural Health Study
cohort is large and many participants reported atrazine use, the
small number of selected cancers occurring during the 6.5-year
average follow-up period prevented estimation of precise effects. In addition, most atrazine applicators were male (99%),
precluding our ability to assess the association between atrazine
exposure and female cancers, including ovarian and breast cancers, which have been associated with exposure to triazine
herbicides (19,22). Our analysis provides limited information on
the timing of pesticide use in relation to disease. Additionally,
with only 6.5 years of follow-up, our ability to make conclusions
concerning latency and secular changes in personal protective
equipment is limited. We will be able to better address these
issues with a longer follow-up period and more exposure data
from subsequent phases of the study. Finally, there are hypotheses concerning gestation and early childhood as periods sensitive to endocrine disruptors (42), and because our study focused
on adult exposures, we cannot address the risk associated with
exposures in early life. Although our study used more detailed
exposure estimates than did earlier studies, estimates for lifetime
days of exposure and intensity-weighted lifetime days of exposure, as well as measures of confounding, include error that
could bias our results toward the null. For example, there is some
variation we could not account for with respect to the categorical
attainment of days exposed in each year. Another source of
variation is the number of hours worked in a day of pesticide
application. Later phases of the Agricultural Health Study will
address these exposure variables and will provide a more precise
estimate of exposure.
Despite the limitations noted above, our prospective study of
cancer incidence among atrazine exposed pesticide applicators
provided an opportunity afforded in few other studies to evaluate
cancer risks associated with exposure to atrazine, while adjusting for other common pesticide exposures and lifestyle factors.
No increased risk of prostate cancer was observed among 554
atrazine exposed cases with increasing exposure to atrazine,
even among those with more than 178.5 days of lifetime use.
Statistical power was limited for some cancers, but certain
intriguing suggestions of association were observed for nonHodgkin lymphoma, multiple myeloma, lung cancer, and bladder cancer, which we intend to monitor and further investigate as
more cases develop in this cohort.
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